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ABSTRACT 
 
Purpose. Melanoma is the most aggressive cutaneous cancer without effective treatment. 
Diagnosis is achieved very often too late and prognosis is poor. Aim of this work is to 
identify proteomic pathways potentially involved in melanoma aggressiveness. 
Materials and Methods. We analyzed 5 human metastatic melanoma cell lines and 
human keratinocyte and melanocyte cell lines as a control. Their proliferation and 
apoptotic behaviors under serum stimulation and starvation were analyzed in order to 
identify the most aggressive one. Melanoma cell proteome from the most aggressive cell 
line (A375), compared to the less aggressive one (SK mel 28), was analyzed by means of 
two complementary approaches: 1) multiplexed assay to measure the levels of  27 
cytokines both in cell extracts and in conditioned media; 2) proteomic study through LC-
MS/MS analysis of cell extracts. Data obtained were analyzed using bioinformatic 
analysis. 
Results. A375 cells were found to possess the highest growth rate both under serum 
stimulation and under serum starvation, while SK mel 28 cells under similar conditions 
were significantly less aggressive, confirmed also by invasion assays. The effect was 
markedly cell-density dependent, suggesting that cell-cell interaction and/or secretory 
signals dependent phenomena are important. Proteome analyses indicated that several 
proteins are differentially expressed and possibly related the aggressiveness. Some of 
these proteins have been identified as transport and proteasome components. The Bio-
Plex analysis of the melanoma cell lines under study indicated that melanoma cells 
contain significantly (p<0.001) different levels of some inflammatory cytokines and 
angiogenic growth factors: the most significantly modified factors were IL-6, Il-7, 
RANTES and VEGF, suggesting a novel interesting viewpoint to explain melanoma cell 
aggressiveness.  
Conclusions. The reported results show that transport, proteasome components and an 
altered cytokine balance may be responsible for human melanoma aggressiveness. 
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1. INTRODUCTION 
 
1.1 TRAITS OF CANCER 
 
Scientific attention is focalized on an important disease: cancer.  
This pathology is considered as by the aberrant cells unable to make functional structures, 
which duplicate unchecked and spread into the organism (Coldizt et al., 2005). Cancer 
cells show acquired traits like uncontrolled proliferation, morphologic alterations, 
transplant capability, resisting cell death and enabling replicative immortality (Hanahan 
and Weinberg, 2011). The differential study of in vivo growth identifies two different 
tumor groups: the first one is the metastatic cancer and the other one is the benign tumor 
(Pontieri, 2004). The uncontrolled proliferation is involved in processes like invasion and 
metastasis that require a sequence of different steps termed metastatic cascade. The 
multistep process begins with proliferation of the primary tumor and basement 
membranes (proliferation and angiogenesis), then tumor invades blood or lymph to a 
distant organ (invasion and circulation), so  tumor cells arrest in a small vessels within the 
distant organ (arrest vessels). Next, cancer cells escape from the lumina of such vessels 
into the parenchyma of distant tissues (extravasation) and the formation of small nodules 
of cancer cells starts (micrometastases). Finally micrometastatic lesions (tumor) grow to 
macroscopic tumors (colonization) [Talmadge, Fidler 2010, Hunter et al, 2008,] (Figure 
1) 
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Figure 1. Metastatic serial steps process (Lentini et.al., 2012 with modifications) 
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1.2. MELANOMA      
 
Melanoma is the most aggressive skin cancer and originates from the malignant 
transformation of melanocytes in the skin and mucous membranes or in eye, meninges 
and inner ear (Miller and Mihm MC Jr , 2006, Grichnik, 2008) (Figure 2).Cutaneous 
Melanoma (CM) is the most common form of melanoma.  
The incidence and mortality of melanoma have steeply increased in the last century, but it 
continues to rise faster than that any other malignancy (Ricker et al., 2010).  
Melanoma increased 15-fold in the last 50 years with a rate of increase of approximately 
3-7% per year (De Giorgi et al., 2012, de Braud et al., 2003) due to many factors like 
environment, improvement of diagnosis and others. Therefore today melanoma is not yet 
considered a rare cancer, above all in the western countries. Many risk factors are 
involved in the tumor growth, like high number of nevi, alteration in an existing nevus, 
adult age, family history positive for melanoma, use of sunbeds and sunlamps and others 
constitutional host factors like phenotypic characteristics (Kari et al, 2011; Nielsen et al, 
2011). Melanoma diagnosis often achieved too late (Psaty et al, 2010). Since prognosis in 
melanoma is directly proportionate to the depth of the neoplasm, early detection of 
melanoma is of crucial importance and accurate early diagnosis, leading to earlier 
treatment, is also extremely significant for a successful management. In fact, when 
melanoma is diagnosed early, it can be cured by surgical excision; nevertheless, 
metastatic melanoma remains generally incurable and is largely resistant to current 
therapies, with a median survival time of 6 to 9 months from the time of diagnosis and a 
5-year survival rate of 5.5% (Walsh et al, 2010).    
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Figure 2. Melanoma origin. 
 
Specific visual features are used to diagnose a melanoma lesion; in particular the 
selection of traits was based on the ABCDE rule, which considers 5 visual criteria.  
(A: lesion Asymmetry; B: Border irregularity; C: Color variegation; D: Diameter > 6mm; 
E: Evolution) (Figure 3). 
 
 
Figure 3. Melanoma features. 
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The Clark and Breslow indexes are used to stage a melanoma lesion (Clark et al., 1984; 
Breslow, 1978) (Figure 4). The evolution process of melanoma performs in two different 
layer of growth: a radial growth phase, which is characterized by intra-epidermal growth 
(Clark’s index) and a vertical growth phase also called the dermal invasion phase 
(Breslow’s index) (Meier et al., 1998). The vertical growth phase requires high 
angiogenic activity, which contributes to a very rapid development of melanoma 
metastatization. 
 
 
 
 
 
Figure 4. Melanoma Development in three different steps: radial (RGP), vertical (VGP) 
and metastatic growth.  
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Although recent discoveries in the complex pathways involved in melanoma development 
created new opportunities for targeted drugs (Russo et al., 2009), the identification of 
novel molecular specific markers and pathogenic mechanisms is still an urgent need. 
The elucidation of the molecular mechanisms likely related to the melanoma 
aggressiveness, may be therefore extremely important to develop novel molecular 
approaches correlating with different stages of the disease, potentially useful for 
diagnostic, prognostic and therapeutic options.   
The major genetic alterations in melanoma involve RAS-RAF- MEK and ERK pathways, 
referred to proliferative signals generated at the cell surface receptors and through 
cytoplasmic signaling into the nucleus (Davies et al., 2002, Russo et al., 2009).  
In normal cells the signaling cascade is activated by the binding of a receptor tyrosine 
kinase on the cell membrane with its respective ligand. This binding activates RAS (a 
membrane-bound protein with GTPase activity) which then recruits RAF that in turn 
phosphorylates and activates MEK. Phosphorylated MEK activates ERK which induces 
several proliferative and survival processes (Inamdar et al, 2010). There are 3 isoforms of 
RAF in human cells: ARAF, BRAF and CRAF. Mutations in BRAF occur in 50-70% of 
melanomas; in particular a substitution of valine by glutamic acid codon 600 in exon 15 
(V600E) accounts in 90% of BRAF mutations in melanomas (Corcoran et al., 2011). 
Mutant BRAF conveys survival signals through different cytoplasm and cytoskeletal 
targets; these signals initiate nuclear transcriptions turning out in expression of several 
cancer-associated genes. ERK activity is involved in immune evasion by melanoma cells 
by the decrease of the immunosuppressive soluble factor IL-10, vascular endothelial 
growth factor, or IL-6. Richmond et al reported that melanoma cells express a variety of 
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cytokines (small cell- signaling molecules), chemokines (chemotactic cytokines) and 
growth factors, and levels of expression are related to melanoma progression (Figure 5). 
A study on nevi, primary and metastatic melanoma lesions demonstrated as primary 
melanomas express low amounts of interleukin-8 (IL-8), tumor necrosis factor (TNF), 
TGF-β and c-kit (Moretti et al., 1999). On the contrary, metastases showed a up-
regulation of IL-1α, IL-1 β, IL-8, TNF- α, TGF-β, granulocyte-macrophage colony 
stimulating factor (GM-CSF). So, it was concluded that IL-6 and IL-8 expression was 
associated with early malignancy, while TGF-β, IL-1α and GM-CSF were highly 
expressed in late metastasis. In particular, TGF- β is considered a marker of metastatic 
spreading (Moretti et al., 1999). Cytokines with known functions for inflammatory and 
immune cells might influence host immune response. Melanoma cells can activate and/or 
reshape their environment to secret metastatic progression factors. Further, melanoma 
cells can secrete inhibitory modulators and stop the recognition and maturation of 
effectors immune cells (Melnikova et al., 2009).  
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Figure 5. Melanoma tumor cells develop CXC and CC chemokines that affect 
angiogenesis, inflammation, the tumor microenvironment, and immune cell response, 
recruitment of leukocytes, tumor growth and metastasis. In particular, melanoma cells 
also express chemokine receptors that guide metastasis to specific target organs. The 
chemokine gradient produced binds and activates these melanoma cell chemokine 
receptors. Chemokines also stimulate production of metalloproteinases that degrade the 
matrix and facilitate melanoma metastasis, so chemokine gradients, guide the metastasis 
progression (Richmond et al., 2009). ECM means Extra Cellular Matrix. 
 
In the last years a large number of biological data were generated and several new 
techniques enable the simultaneous detection of different modified elements. The 
OMICS sciences (Genomics, proteomics, transcriptomics, metabolomics and many 
others) use these high-throughput (HT) screening techniques to generate at the same time 
a large amount of data about genes, gene expression or proteins network. (Schneider MV 
et al., 2011).  
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1.2.1. THERAPEUTIC APPROACHES  
 
The therapeutic approaches to melanoma depend on the stage of the tumor and they can 
be summarized as follows: 
 Resection: surgery removal of the tumor and of the surrounding healthy tissue.  
 Radiotherapy: the irradiation with high-energy ionizing electromagnetic rays 
blocks the growth and destroys cancer cells. This is a local therapy that attack a 
specific and detailed area, thus is not suitable to treat tumor too widespread. 
 Chemotherapy: use of drugs that, through the blood circle, reach the tumor site 
and destroy cancer cells in a no-selective manner. Dacarbazine (5(-3, 3Dimehtyl-
Triazenyl-Imidazole-4Carboxamide, DTIC) cisplatin (CDDP), methotrexate (MX) 
and others are used as chemotherapy drugs, each of them acting with different 
mechanism of action.  
 Immunotherapy: treatment of cancer by inducing, enhancing, or suppressing an 
immune response; interferon- alpha (IFN-α) and interleuchin-2 (IL-2) are the most 
studied. In particular, IL-2 acts modulating effector cells, T-cells, NK (Natural 
Killer) and LAK (Lymphokine-Activated Killer). Regulatory T cells and myeloid-
derived suppression cells seem to play an important role in inducing tolerance and 
in the down-regulation of immune response to tumor antigen, through the 
production of immune suppressive IL-10, transforming growth factor beta (TGF-
beta), and  the  expression of inhibitory molecules such as cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is expressed on the activated 
T- lymphocytes and exerts a suppressive effect on the induction of immune 
responses after interaction between T-cell receptor (TCR) and human lymphocyte 
antigen (HLA) peptide molecules on the antigen presenting cell (APC).  The 
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CTLA-4 block may enhance antitumor responses by allowing the immune system 
responsiveness against an antigen. Blocked CTLA-4 using anti-CTLA-4 
monoclonal antibodies exert a tumor regression activity, so these antibodies are 
using as immunotherapy drug (Del Vecchio et al., 2011). 
 Differentiation therapy: differentiation is the process by which totipotent cells (or 
pluripotent), initially identical and derived from a common progenitor element, 
acquire different characteristics that allow them to reach a structural and 
functional specialization. This phenomenon is essentially based on the 
transcription regulation, microRNA regulation and differential synthesis of 
specific proteins, in response to signals coming from the extracellular 
environment. Within a single organism, therefore, variously differentiated cells 
have the same genotype, but they may present phenotypes also very dissimilar, 
attributable to a different regulation of gene expression. So these cells are, 
distinguishable both for morphological characteristics and their molecular 
composition. Differentiation occurs, as a rule, during embryonic development and 
it is the basis of histogenesis and organogenesis; otherwise, differentiation plays 
an important role during post-natal life, existing in some tissues, such as bone 
marrow. The concept of differentiation therapy stems from the observation that 
some molecules, synthetic or natural, can stop the growth of cancer cells by 
inducing the differentiation and bring back cells to assume the same morphology 
and function of cells of the origin physiological tissue. This therapeutic approach 
does not set eradicating the cancer, but is able to block the growth and metastatic 
progression; also, unlike chemotherapy, it seems to be a more selective approach 
towards malignant cells and less toxic. One of the greatest achievements in this 
field was obtained with the administration of trans-retinoic acid in patients with 
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acute promyelocytic leukemia: in most cases, this molecule has led to partial 
clinical remission of the disease (Thiele et al., 2000). It is also important to 
emphasize that many molecules of natural origin show a significant differentiating 
power: genistein (a flavonoid) induces, in fact, a dendritic phenotype and an 
increase in melanin synthesis in murine melanoma cells (Hartmann et al., 1997); 
while, naringenin (a flavonoid) (Lentini et al, 2007), methylxanthines (caffeine, 
theophylline and theobromine) (Beninati, 1995) and antraquinones (aloin, aloe-
emodin etc) ( Tabolacci et al., 2011; Rossi et al., 2010; ) are capable of inducing 
terminal differentiation of tumor cells likely through the activation of the enzyme 
transglutaminase as regulator of cancer metastasis (Lentini et al., 2012).  
 Combination therapy: very often surgery, systemic medical therapy and 
radiotherapy are not-sufficient to eradicate the tumor. In particular, treatment of 
distant metastatic melanoma is unable to obtain a survival advantage. For this 
reason, a combination of different drugs with different mechanism of action and 
other therapeutic approaches, are used (Ascierto et al., 2012). 
 
 
1.2.2. CYTOKINES, CHEMOKINES AND GROWTH FACTORS 
 
Cytokines (Greek “cyto-, cell; and “-kinos”, movement) are a family of signaling 
molecules that mediate and regulate immunity, inflammation, hematopoiesis, and many 
other cellular processes (Feldmann, 2008). Cytokines were at first identified as products 
of immune cells that act as mediators and regulators of immune process. Non-immune 
cells also produce cytokines which can have effects on non-immune cells as well.  
Cytokines alter the body’s response to cellular damage or invasive pathogens. The first 
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cells to secrete cytokines in response to injury are epithelial and endothelial cells that 
initiate a potent immune response. The innate immune cells generate a range of cytokines 
and regulate macrophages/monocytes, dendritic cells (DCs), natural killer (NK) cells, 
mast cells, eosinophilis, and neutrophilis. Cytokines is the term used to refer to the 
immunomodulating agents, such as interleukin and interferons.  Each cytokine bind cell-
surface receptor; the interaction with the receptor, actives subsequent cascades of 
intracellular signaling then alter cell function. Cytokines can be characterized as autocrine 
(self modulating), paracrine (modulating cells in the immediate surroundings), juxtacrine 
(modulating through cell membrane signaling), retrocrine (modulating to stop host 
defense). The effects of cytokines are often pleiotropic, redundant, synergyc and 
antagonist and form a network (Grotzinger, 2002).  
Since a unifying classification is still lacking, cytokines are identified by numeric order of 
discovery, by a given functional activity, by kinetic or functional role in inflammatory 
responses (early or late, innate or adaptive, pro-inflammatory or anti-inflammatory), by 
primary cell of origin (monokine = monocyte derivation; lymphokine = lymphocyte 
derivation), and, more recently, by structural homologies shared with related molecules 
(Kelso, 1998). It can be possible to identify cytokines as long and short chain structure, 
however these molecules can be classified also on their main function (Abbas et al., 
2002). A variety of cells are capable of making cytokines, but the biggest producers are 
macrophages and T-helper lymphocytes. Cytokines are involved in hematopoiesis, 
adaptive immunity, innate immunity and inflammation. Cytokines have been classified 
as, interleukins (IL), interferon (INF), tumor necrosis factor (TNF), colony stimulating 
factor (CSF), chemokines and growth factors (Table 1). The term “interleukin” is used to 
identify cytokines that have the ability to act as signal molecules among different 
population of leukocytes (IL-1~IL-29). Interferons are a group of glycoproteins produced 
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by human or animal cells following the infection of virals and exposure to various 
inducing agents (INF-α; INF-β; INF-γ). TNFs (TNF- α; TNF-β) are known to have a 
multiplicity of actions. Colony stimulating factors (CSFs) [multi-CSF (IL-39); 
granulocyte macrophage-CSF (GM-CSF); monocyte-CSF (M-CSF); granulocyte-CSF (G-
CSF); stem cell factor (SCF), erythropoietin (EPO)] stimulate proliferation or 
differentiation of pluripotent hematopoietic stem cells and different progenitors. 
 
INTERLEUKINS IL-1α/β, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 23, 27 
INTERFERONS IFN-α, β, γ, Ω 
COLONY-
STIMULATING 
FACTOR G-CSF, GM-CSF, M-CSF, EPO, IL-3, MEG-CSF, SCF 
IL6 FAMILY IL-6, IL-11, CNTF, CT-1, OSM, LIF, NNT,-1/BSF-3 
TNF FAMILY 
TNF-α, TNF-β, LT-β, FasL, CD40L, CD27L, CD30L, NGF, TRAIL, 
TRANCE, APRIL, LIGHT, THANK, TALL-1 
GROWTH FACTOR 
FGFs, CTAP-3, EGF, ECGF, HGF, IGFs, PDGFs, PAF, TGFs, KGF, 
CTGF, GDF-15/MIC-1, Fibrosin 
CHEMOKINES 
C: lymphotactin 
CC: MPC-1,2,3,4, RANTES, MIP-1s, MIP-3,4,5, eotaxin 
CXC: IL-8, PF-4, NAP-2, GROs, ENA-78, IP-10, Mig 
CX3C: fractalkine 
Others: IL-16, ecalectin 
 
Table 1. Cytokine classification (Xing and Wang, 2000). 
 
Cytokines are involved in a very elaborate network that is composed of two different 
immune mechanisms: innate and adaptative response (Abbas et al., 2002) (Figure 6). 
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Figure 6. Cytokines network  
 
Chemokines are a family of small cytokines or proteins secreted by cells. They have 
ability to induce directed chemotaxis in nearby responsive cells; they are chemotactic 
cytokines. Proteins are classified as chemokines if they share structural hallmarks such as 
small size (8-10 kDa, with the mature peptide comprising between 70 and 120 amino 
acids), and the presence of four cystein residues inconserved locations that are important 
to form their 3-dimensional shape. Chemokines are classified into subfamilies denoted as 
CXC (one amino acid between the first two cysteine residues), CC (lacking the amino 
acid between the first two cysteine residues), CX3C (three amino acids between the first 
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two cysteines), and C (lacks one cysteine in the first pair of cysteine residues) (Richmond 
et al, 2009 ; McColl, 2002)( Figure 7). 
 
 
 
Figure 7. General structure of chemokine superfamily members (McColl, 2002). 
 
Chemokines (L) bind to each specific receptors (R). In the table 2 the chemokines 
nomenclature is reported.  
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Chemokine ligand nomenclature 
Systematic name Original names/s 
 
Human Mouse 
CXCL1 MGSA, gro-α KC 
CXCL2 MIP-2α, gro-β MIP-2* 
CXCL3 MIP-2β, gro-γ 
 CXCL4 PF4 PF4 
CXCL5 ENA-78 LIX 
CXCL6 GCP-2 CKα-2 
CXCL7 NAP-2 ? 
CXCL8 IL-8, NAF, NAP-1 ? 
CXCL9 Mig Mig 
CXCL10 IP-10 Crg2 
CXCL11 I-TAC I-TAC 
CXCL12 SDF-1α, SDF-1β SDF-1 
CXCL13 BLC, BCA-1 BLC, BCA-1 
CXCL14 BRAK, Bolekine BRAK 
CXCL15 ? Lungkine 
CXCL16 CXCL16 CXCL16 
CCL1 I-309 TCA-3 
CCL2 MCP-1, MCAF JE 
CCL3 MIP-1α, LD78α MIP-1α 
CCL4 MIP-1β, LD78β MIP-1β 
CCL5 RANTES RANTES 
CCL6 ? C10, MRP-1 
CCL7 MCP-3 MARC 
CCL8 MCP-2 MCP-2 
CCL9/10 ? MRP-2, CCF18, MIP-1γ 
CCL11 Eotaxin Eotaxin 
CCL12 ? MCP-5 
CCL13 MCP-4 ? 
CCL14 HCC-1 ? 
CCL15 HCC-2, Lkn1, MIP-1δ ? 
CCL16 HCC-4, LEC LCC-1 
CCL17 TARC TARC 
CCL18 DC-CK1, MIP-4, PARK, AMAC-1 ? 
CCL19 MIP-3β, ELC, exodus-3 MIP-3β, ELC, exodus-3 
CCL20 MIP-3α, LARC, exodus-1 MIP-3α, LARC, exodus-1 
CCL21 6Ckine, SLC, TCA-4, exodus-2 6Ckine, SLC, TCA-4, exodus-2 
CCL22 MDC, STCP-1 ABCD-1 
CCL23 MPIF-1 ? 
CCL24 MPIF-2, eotaxin-2 ? 
CCL25 TECK TECK 
CCL26 Eotaxin-3 ? 
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CCL27 CTACK, ILC ALP, CTACK, ILC, Eskine 
CCL28 CCL28 CCL28 
CXCL1 Lymphoctactin, SCM-1, ATAC Lymphotactin 
CX3CL1 Fractalkine Neurotactin 
 
 
Table 2. Systemic nomenclature introduced at the 1998 Gordon Conference on 
chemokines (McColl et al., 2002).  
 
 
The role of Chemokines is to act as chemoattractant to guide the migration of cells 
through an increasing their gradient towards the source of the chemokine. Chemokines 
have an important role during both processes of immune surveillance and in development 
and inflammation. In particular, McCool suggests that chemokines can play an important 
role at several stages of DC (Dendritic Cell) development and function. Basal chemokines 
production and expression on the surface of endothelial cells can mediate DC precursor 
recruitment and differentiation of precursor to the immature DC.  
Growth factors are subfamilies of cytokines capable of stimulating cellular growth, 
proliferation, differentiation. The growth factors belonging to cytokines family are: 
transforming growth-factors (cytokines which stimulate the growth of their target cells 
[transforming growth factor-β (TGF-β)]; epithelial growth factor (EGF); vascular 
endothelial cell growth factor (VEGF); fibroblastic growth factor (FGF). 
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2. AIM    
 
Human cutaneous metastatic melanoma is the most aggressive skin cancer without 
effective therapies (Bandarchi et al., 2010). Presently systemic treatment for metastatic 
melanoma, including   both cytotoxic and immunologic therapies, produces low rates of 
response (Sekulic et al. 2008). Human metastatic melanoma shows a very fast invasion 
and progression mechanism, and very often the actual therapeutic approaches are unable 
to contrast the evolution of cancer. So, there is an urgent need for effective novel 
therapies directed to attack the cause of the malignancy and molecular targets to arrest 
cancer progression. So, aim of this thesis is to understand the mechanisms related to 
melanoma aggressiveness that is related to a high proliferation rate, high invasion 
capability and high metastatic power. In particular, using different human melanoma cell 
lines as models of study, our first aim was to identify groups of melanoma cell lines 
highly different in aggressiveness and malignancy.  After that, it is useful to study the 
differential protein expression of these cell lines using proteomic multi-approaches to 
identify potential molecules responsible of the malignancy. Recently the translational 
medicine, a new approach to the medicine based on the translational of novel approaches 
from bench of biomedical researchers to the bed of patients, is focalized on information 
derived from human experimentation and optimizes the interaction between the basic and 
clinical research (Wehling, 2008). For this reason, a specific goal of our study is to verify 
our results in specimens from patients and so act at different levels of study. Clarke and 
colleagues reported that cancer stem cells have a key role in cancer progression because 
they are a reservoir of self-sustaining cells with the unique ability to self-renew and 
maintain the tumor. These cancer stem cells can divide and expand the cancer stem cell 
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pool and to differentiate into the heterogeneous nontumorigenic cancer cell types. These 
cells in most cases seem to constitute the bulk of the cancer cells within the tumor (Clarke 
et al., 2006). Therefore, an additional target of this study is to investigate the cancer stem 
cells behaviors to find putative molecules and/or pathways related to the melanoma 
aggressiveness potentially useful to delay and revert this melanoma characteristic. 
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3. MATERIALS AND METHODS  
 
a. Cell culture 
Human metastatic cutaneous melanoma cell lines used in the present study were: 
SK mel 28, and A375 (purchased and authenticated from the American Type 
Colture Collection, ATCC, Manassas, VA), Mel-397 (kindly supplied by Dr. 
Stefania D’Atri, IDI-Roma), SK mel 110 (Faraone et al.,2009), human 
keratinocyte cell line HaCat (CLS, Eppelheim, Germany) and human Melanocytes 
(Cascade Biologics, Portland, OR, USA). In preliminary experiments, additional 
human melanoma cell lines (WM-115, SK 120, SK 147, and M14 from 
estabilished culture) have been used (not shown).  HaCat and A375  were grown 
for the specified time in complete medium in Dulbecco’s modified Eagle’s 
medium (DMEM; Hyclone, South Logan, UT) and supplemented with 10% fetal 
calf serum (FCS) (Sigma-Aldrich, St. Louis, MO) 2 mM L-glutamine, and 100 
IU/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA) in humidified 5% CO2 
atmosphere, at 37 °C and, when required, under serum deprivation. Mel 397, SK 
mel 28 and SK mel 110 were grown in RPMI 1640 (Hyclone) 10% FCS, 2 mM L-
glutamine, and 100 IU/ml penicillin/streptomycin, and, when required, under 
serum deprivation. Melanocytes were cultured in MGM4 medium according to 
supplier’s instructions (Life Tecnologies, Painsley,UK). Cells were counted by 
hemocytometer and viability was measured by Trypan blue assay. Human 
metastatic stem cell clones, Mel 1 and Mel 3 (kindly supplied by Dr. Adriana 
Eramo, ISS-Roma) were also used. Cancer stem cells were cultured in serum-free 
medium containing 50 µg/ml insulin, 100 µg/ml apo-transferrin, 10 µg/ml 
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putrescine, 0.03 mM sodium selenite, 2 µM progesterone, 0.6% glucose, 5mM 
HEPES 0.1% sodium bicarbonate, 0.4% bovine serum albumin (BSA), glutamine 
and antibiotics, dissolved in DMEM-F12 medium (Gibco-Invitrogen, Carlsbad, 
CA) and supplemented with 20 µg/ml EGF and 10µg/ml bFGF. Flasks non-treated 
for tissue culture were used in order to reduce cell adherence and support growth 
as undifferentiated tumor-spheres. Medium was replaced or supplemented with 
fresh growth factors twice a week until cells started to grow forming floating 
aggregates. Cultures were expanded by mechanical partial dissociation of spheres, 
followed by re-plating of cells and residual small aggregates in complete fresh 
medium.  
 
b. Proliferation assay  
Semi-confluent cells were harvested, plated and propagated in medium containing 
10% FBS in 6 well plates at 3 different densities: high (9x10
4 
cells/well), 
intermediate (6x10
4 
cells/well), low (2x10
4 
cells/well) as previously reported 
(Faraone et al., 2009). The day after, two of the six wells were washed with PBS 
w/o calcium and magnesium and cells were harvested using Trypsin/EDTA 
(Euroclone) and counted with a Burker chamber (this number represents the T0). 
Media of other remaining wells were removed, cells were washed with PBS and 
medium was then replaced with serum-free medium. Cells were photographed, 
washed using PBS, harvested with trypsin/EDTA and counted with a Burker 
chamber after 24 and 48 hours of serum deprivation (Figure 8).  All experiments 
were carried out at least 3 times in duplicate.  
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Figure 8. Schematic representation of the Proliferation Assay.  
 
 
c. Invasion assays  
Invasion assays were performed in Boyden Chamber as described (Aguzzi et al., 
2004 ; Albini et al., 1987). Polycarbonate polyvinylpyrrolidone free membranes (8 
µm pore size, Costar, Cambridge, MA), were coated with 0.5 mg/ml Basement 
Membrane Matrix Matrigel (BD Biosciences, Franklin Lakes, NJ). Cells were 
allowed to invade, using fetal bovine serum (FBS) as chemoattractant, for 5 h at 
37 °C. The membrane was fixed in ethanol and stained with toluidine blue (2%). 
After the removal of non-migrating cells on the upper side of the membrane, the 
number of invasive cells was evaluated by means of the 4 field (x400). 
 
d. Cell extract preparation 
Postnuclear cell lysates were prepared using the following lysis buffer: NaCl  
0.150 M, Igepal CA-630 (Sigma-Aldrich) 1%, Tris (hydroxymethyl) 
aminomethane 20mM, complete EDTA-free Protease Inhibitor Cocktail Tablets 
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(containing PMSF, Pefabloc Sc, Aprotinin, Leupetin, Pepstatin)(Roche, Milan, IT) 
and phophatase inhibitor  (Sodium Floride 40mM and orthovanadate 1mM). Cells 
were plated in 100 mm Petri dishes (Corning, NY, USA) at an intermediate 
density (6x10
5 
cells/well) in complete medium. The day after, cells were washed 
with PBS w/o Calcium and Magnesium and then replaced with a serum-free 
medium. After 48h of serum-deprivation, cells were washed 2 times with PBS 
(Euroclone), then 300 µl of lysis buffer were added and cells were harvested and 
cell lysates were collected using a scaper. Cell lysates were collected and 
incubated 20 minutes on ice. After that, the extracts were centrifuged at 13200 
rpm x 10 minutes at 4 °C in an Eppendorf Centrifuge 5415R and the soluble 
fraction was collected. The protein concentration of each cell extract was then 
measured by Bradford's protocol (Bio-Rad kit, Bio-Rad Laboratories, Hercules, 
CA) according to the manufacturer’s instructions, using a cuvette 
spectrophotometer (Uvikon 860 Instrument, Kontron, Zurich, CH). 
 
e. Programmed cell death analysis  
Cells were grown in 6 wells plastic plates (Corning Inc.), trypsinized and at the 
specified time of growth, harvested (floating and attached cells) and fixed in 70% 
cold ethanol. Fixed cells were washed and incubated with 200 μg/ml ribonuclease 
A (RNase A, Life Tecnologies) for 30 min at 37 °C and 50 μg/ml  Propidium 
Iodide (PI) and gated out electronically as previously described (Facchiano et al. 
2001). The relative DNA content and cells distribution in various cell cycle 
compartments were determined with a FACScanto Becton Dickinson Instrument 
(Becton Dickinson, CA, USA) and the FACS Diva software (5.0.3 version).  
 
Materials & Methods 
 
26 
f. Differentiation and culture of stem cells  
Differentiation of melanosphere forming cells was obtained by replacing stem cell 
medium with Melanocyte Growth Medium (MGM4, Lonza, East Rutherford, NJ) 
and they were cultured in tissue culture-treated flasks, to allow cell attachment 
and differentiation toward the melanocytic lineage. Cells were harvested and 
conditioned media were taken after four days of differentiation (PC cells).  PC 
cells were washed with PBS and fresh medium was replaced; after four days 
conditioned media were taken (PC
+ 
cells). 
 
g. Cytokines and growth factor analysis: the Multiplex approach  
Cytokines and growth factors were measured by using a Bio-Plex Pro human 
cytokine 27-plex panel (Bio-Rad Laboratories, Hercules, CA) as described ( 
Tabolacci et al., 2011) for  the following analytes: IL-1Ra, IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, TNF-α, IFN-γ, MIP-
1α, MIP-1β, Eotaxin, MCP-1, G-CSF, GM-CSF, basic FGF, VEGF, IP-10, 
RANTES, and PDGFbb. Conditioned media were collected, centrifuged and 
concentrated (from 10X to 100X) using a centrifugal filter units with microporous 
membrane (YM-3). The protein concentration was then measured as above 
described. Twenty five micrograms of proteins from total cell lysates were 
analyzed, according to the manufacturer’s instructions. The analysis was carried 
out using 50 µl of the sample.  After the incubation with antibodies-activated 
magnetic beads, samples were washed using a Bio-Plex Pro 
TM
 Station (Bio-Rad). 
The quantification was carried out on a Bio-Plex Array Analyzer (Bio-Rad) by a 
Bio-Plex Manager Software version 4.1.1. Results expressed as pg/ml were 
analyzed by a Bio-Plex Manager Software version 6. Normalization of samples 
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was achieved by correcting for the protein concentration and for number of 
harvested cells.  
 
h. Electrophoresis 
The protein electrophoretic profile of the melanoma cell lines and HaCat lysates 
was analyzed using gels (2.4 -15% continuous acrylamide-bisacrylamide gradient 
vertical gels, manually poured into 16×18 cm, thickness 1.5 mm, 15 wells) 
generated with a gradient maker (Model 385, Bio-Rad, Hercules California, US) 
and run with the SE 600 Ruby Apparatus (Hoefer, Inc. Holliston,MA), using fresh 
solutions as described (Facchiano et al 2010). The gel stacking region was hold. 
Protein extracts were also separated on 4–15% Mini-PROTEAN® TGX™ pre-cast 
polyacrylamide gel (8.6 x 6.7 x 0.1, Bio-Rad) as pubblished (Verdoliva et.al 
2013). 
 
i. Immunological analysis   
Whole cell lysate (40 μg per well/120 μg per well), separated on 4–15% Mini-
PROTEAN
®
 TGX™ pre-cast polyacrylamide gel Bio-Rad), blotted onto 
nitrocellulose membrane (GE Healthcare, Chalfont St. Giles, UK), was probed 
with rabbit anti-caspase 3 (1:1000, Cell Signaling, MA, USA) or anti-β actin 
(1:5000, Abcam, MA) in milk 1.25% TPBS 0.1% for 1 h at RT. After the 
membrane was washed three times with PBS-T(0.1% Tween 20 in PBS, pH 7.4) 
for 10 min, incubated in the appropriate HRP-conjugated secondary antibody  at 
room temperature for 1 h. Horseradish peroxidase-conjugated secondary 
antibodies (Pierce) were used, followed by chemiluminescence according to 
manufactory’s instracture (ECL; Euroclone Milan,IT). 
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j. Mass spectrometry analysis  
For protein identification, the total lane of the gel was cut, proteins were reduced, 
alkylated and digested overnight with bovine trypsin sequencing grade (Roche 
Applied Science, Monza, IT) according to a standard protocol. Peptide mixtures 
were analyzed by nanoflow reversed-phase liquid chromatography tandem mass 
spectrometry (RP-LC-MS/MS) using an HPLC Ultimate 3000 (DIONEX, 
Sunnyvale, CA) connected on line with a linear Ion Trap (LTQ, ThermoElectron, 
San Jose, CA). Peptides were desalted in a trap column (Acclaim PepMap 100 
C18, LC Packings, DIONEX) and then separated in a reverse phase column, a 10 
cm long fused silica capillary (Silica Tips FS 360-75-8, New Objective, Woburn, 
MA), slurry-packed in-house with 5 μm, 200 Å pore size C18 resin (Michrom 
BioResources, CA) as described (Facchiano et al. 2012). Peptides were eluted 
using a linear gradient from 96% A (H2O with 5% acetonitrile and 0.1% formic 
acid) to 60%B (ACN with 5% H2O and 0.1% formic acid) in 40 min, at 300 
nl/min flow rate. Analyses were performed in positive ion mode and the HV 
Potential was set up around 1.7-1.8kV. Full MS spectra ranging from m/z 400 to 
2000 Da were acquired in LTQ mass spectrometer operating in a data-dependent 
mode in which each full MS scan was followed by five MS/MS scans, where the 
five most abundant molecular ions were dynamically selected and fragmented by 
collision-induced dissociation (CID) with normalized collision energy of 35%. 
Target ions already fragmented were dynamically excluded for 30 s. Tandem mass 
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spectra were matched against Swissprot database and through SEQUEST 
algorithm (Yates et al., 1995) incorporated in Bioworks software (version 3.3, 
Thermo Electron) using fully tryptic cleavage constraints with the possibility to 
have one miss cleavage permitted, static carbamidomethylation on cysteine 
residues and methionine oxidation as variable modification. Data were searched 
with 1.5 Da and 1 Da tolerance respectively for precursor and fragment ions. A 
peptide has been considered legitimately identified when it achieved cross 
correlation scores of 1.8 for [M+H]1+, 2.5 for [M+2H]2+, 3 for [M+3H]3+, and a 
peptide probability cut-off for randomized identification of p<0.001. Protein and 
peptide false discovery rate (FDR) was calculated dividing the number of false 
hits by the number of positive hits where the false hits are evaluated using a decoy 
database directly constructed by Bioworks software on the same human database 
used for the target search and adopting the same scoring criteria.  
 
 
k. Bioinformatic analysis   
The bioinformatic analysis of data was performed through DAVID portal 
(http://david.abcc.ncifcrf.gov/ )(Huang et al., 2009a, 2009b; Facchiano et al., 
2003). In particular proteins, identified by the UNIPROT accession number, were 
classified using several parameters (e.g. functional annotation chart, KEGG 
analysis of pathways). Moreover, to confirm the proteomic and Bio-Plex results, 
data from microarray dataset were analyzed through Gene Expression Omnibus 
(GEO, http://www.ncbi.nlm.nih.gov/gds ). 
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l. Statistical analysis  
All experiments were repeated three times, and the results are expressed as the 
mean ± SD (standard deviation) of three different determinations. Data were 
analyzed by the t-Student test, differences were considered highly significant 
when p<0.05. 
 
 
4.  EXPERIMENTAL RESULTS 
 
I.  Cell proliferation studies  
 
Human cutaneous metastatic melanoma cell lines, melanocyte cell line and a keratinocyte 
cell line were used to investigate and compare the aggressiveness of several cancer cell 
lines. Tumor aggressiveness includes migration, invasion, cell proliferation, angiogenesis 
capabilities of metastatic cells (White et al., 2011). This study allowed identifying the 
most and the less aggressive melanoma cell lines to be used for further analyses. Cell 
lines were seeded at three different densities identified as low (20,000 cells/well), 
intermediate (60,000 cells/well) and high (90,000 cells/well). Cells were grown in serum-
free medium (Figure 9A,9B,9C) and in complete medium supplemented with 10% FCS 
(Figure 9D) and cell number was measured at 24 and 48 hours of serum deprivation by 
counting with and hemocytometer. Cell viability was checked by the Trypan blue assay 
(Rossi et al 2010). Different growth properties were observed in the different cell lines. 
SK mel 110 and A375 cells showed a higher growth rate in both conditions (Fig.9A, B, C, 
and D). On the contrary, SK mel 28, Mel 397 and HaCat cells, showed a lower growth 
rate under starvation conditions (Fig. 9A, B, C). Moreover, SK mel 110 and A375 in 
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serum-free medium and  seeded in a low density (30,000/well), showed after 24 hours a 
252.26% growth rate (time 0),  and a 260 % growth rate after 48 hours, compared to cells 
at time 0 (T0), reported as 100%. A375 under the same conditions showed after 24 hours 
a 154.67% growth rate and 259% growth rate after 48 hours, in respect of cells at T0. 
Unlike SK mel 28 and Mel 397 cells under the same conditions showed a 88.35% growth 
rate after 24 hours and 119.90% and 68.75% after 48 hours, respectively. HaCat cells 
showed after 24 hours a 198% growth rate and 228.78% after 48 hours (Fig. 1A). Cells 
seeded at 90,000/well (high density) showed a different trend compared to the low density 
condition. SK mel 110 showed a 279.05% growth rate after 24 hours and a 343.2% 
growth rate after 48 hours. A375 cell line revealed after 24 hours a 248.16% growth rate 
and after 48 hours a 309.76% growth rate. SK mel 28 and Mel 397, showed after 24 hours 
a 136.74% and 92.2% growth rate respectively, and showed after 48 hours a 256.34% and 
100.61% growth rate. HaCat cells after 24 hours and 48 hours showed a 238.8% and 
301.34% growth rate respectively. Cells seeded at 60,000/well (i.e. intermediate density) 
showed intermediate behaviors, indicating that the observed effects are cell-density 
dependent indeed. All these results are summarized in the following figure (Figure 9). 
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Figure 9. Growth Rate of Human Metastatic Melanoma Cell Lines. Panel (A)- (F) show 
growth rate of SK mel 110, SK mel 28, A375 and Mel 397 metastatic melanoma cells and 
human HaCat keratinocytes, in serum free-medium and at three different densities; (A) 
low density, (B) Intermediate density, (C) high density. Panels (D) show the growth rate 
of the same 5 cell lines in 10% FCS supplemented medium. Each data point represents 
the mean of three different determinations. Asterisks indicate statistical significance 
(p<0.05), comparing most to the less aggressive at the same time point. 
 
 
This studies allow to identify two different group of cell lines that differ significantly for 
growth rate; SK mel 110 and A375 (high growth rate) and SK mel 28 and Mel 397 (low 
growth rate). Starting from this observation, for our study we choose A375 cell line and 
SK mel 28 as models to study the melanoma aggressiveness (Figure 10).   
 
 
 
 
Figure 10. A375 and SK mel 28 cell line under serum deprivation.  
 
II. Invasion assay 
Invasion capability of SK mel 28 compared to A375 cell line, estimated by a Boyden 
Chamber assay, was impaired. The analysis performed on MG-coated porous filter, 
indeed, showed a high invasive power of the most aggressive (A375) compared to the less 
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aggressive (SK mel 28) cells; in particular a mean of 42 and 5cell per field were counted 
respectively (Figure 11).  
 
 
 
 
 
 
Figure 11 Assessment of cell invasion SK mel 28 and A375 cell lines by Boyden 
Chambers assay. A375 resulted more invasive compared to SK mel 28 cells 
Quantification of the invasion is expressed as the number of invasive cells per field. Top 
of the panel, representative micrographs of Boyden Chambers invasion assay (400× 
magnification). 
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III. Cell death analysis  
To elucidate the consequence of the serum deprivation on the A375 and SK mel 28 
proliferation, we evaluated the DNA content using flow cytometry after PI staining of 
nuclei.  As shown in figure 12, the percentage of apoptotic cells under serum deprivation 
conditions (measured as sub-G1 population) was significantly higher in SK mel 28 cells 
than that measured in A375 cells (15.8% versus 3.3%, p<0.05). 
 
 
 
 
 
 
Figure 12. Apoptosis evaluation of A375 and SK mel 28 cell grown in a complete 
medium (A and C) and in a serum-free medium (B and D) . Flow cytometric analysis 
of the cellular DNA content was performed after propidium iodide staining, and the 
Experimental Results 
 
37 
subG0/G1 region represents the apoptotic cell population. Data were expressed as the 
percentage of total cells. Each point represented the mean ± SD of three different 
determinations. 
 
 
 
IV. Cytokines  and Growth Factors Analysis 
Multiplex assay using the Bio-Plex technology (see methods) measured the content of 27 
human cytokines and growth factors in protein extracts and in conditioned media from 
melanoma cell lines and stem cells under study. Data obtained, show in cell extracts 
(Table 3a) cytokines levels that result not significantly modified and they are following 
reported: PDGF-bb; IL-2; IL-4; IL-5; IL-10; IL-15; IL-17; G-CSF; GM-CSF; MIP-1b; 
and TNF-α. Otherwise, comparing A375 and SK mel 28 extracts, the most and the less 
aggressive cell lines respectively, we identified significantly different levels of some 
inflammatory cytokines and angiogenic growth factors, the modified analytes were IL-6, 
IL-1ra, IL- 1 β, IL-7, IL-8, IL-9, IL-12, Eotaxin, FGF-basic, INF-γ, RANTES,  and 
VEGF . In particular, data show (Table 3b) that PDGF-bb, IL-1β, IL-1ra, IL-8 resulted 
higher in SK mel 28 than A375, while IL-6, IL-12 and VEGF were lower in SK mel 28 
than A375 extracts.  
In A375 conditioned media IL-1ra, IL-6, IL-7, IL-9, IL-12, Eotaxin, Rantes and VEGF 
are increased (p<0.001) while IL- 8 is reduced in A375 conditioned media when 
compared to SK mel 28 (p<0.001). 
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CYTOKINES LEVELS INCELL EXTRACT 
 SK mel 28 A375 
 PDGF-bb   2.75 ± 1.54 0.44 ± 0.39    * 
 IL-1b   9.07 ± 8.21 9.07 ± 8.21* 
 IL-1ra   3.20 ± 0.78 1.49 ± 0.71     * 
 IL-2   OOR OOR 
 IL-4   0.02±0.01 0.03±0.02 
 IL-5   OOR 0.02±0.02 
 IL-6   0.07 ± 0.08 127.42 ± 0.08  ** 
 IL-7   0.40 ± 0.06 0.03± 0.05 
 IL-8   81.97± 22.80 4.09 ± 0.08     * 
IL-9  0.16 ± 0.05 0.25± 0.18 
IL-10  OOR OOR 
 IL-12  2.3 ± 0. 54 31.97 ± 1.08   ** 
 IL-13   0.09 ± 0.08 0.03 ± 0.02 
 IL-15   OOR OOR 
 IL-17   OOR 0.03 ± 0.01 
 Eotaxin  0.68 ± 0.30 0.41  ± 0.36 
 FGF basic  4.09 ± 0.98 11.36  ± 10.87 
 G-CSF  2.11±2.06 18.66±16.03 
 GM-CSF  0.28±0.24 0.28±0.17 
 IFN-g  0.61±0.10 0.78±0.32 
 IP-10  34.37±19.22 0.46±0.27 
 MCP-1  OOR 8.56±8.10 
 MIP-1a  OOR 2.66±1.76 
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 MIP-1b  0.78±0.28 2.16±1.66 
 RANTES  0.54 ± 0.04 1.50 ± 1.20 
 TNF-a  OOR 0.07± 0.6 
 VEGF  4.56 ± 1.54 257.38 ± 59.25 ** 
 
Table 3a. Twenty seven human cytokines and growth factors levels have been measured 
(data are reported as pg/ml). The most significantly modified are shown *= p<0.005 or 
**= p<0.001. ORR (Out Of Range) identifies analytes that are not detectable by the assay.   
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CYTOKINES LEVELS IN CONDITIONED MEDIA  
 SK mel 28 A375 
PDGF-bb OOR OOR 
IL-1b OOR 0.03± 0.04 
IL-1ra 28.17 ± 3.30 48.61 ± 3.38 * 
IL-2 1.67 ±1.89 2.36 ±2.34 
IL-4 0.06±0.10 1.33±1.66 
IL-5 OOR 0.10±0.14 
IL-6 1 ± 0.04 6.75 ± 1.06 ** 
IL-7 0.40 ± 0.06 6.52 ± 4.89 ** 
IL-8 116.96 ± 5.25 2.75 ± 1.06 ** 
IL-9 9.50 ± 3.67 1686.88 ± 5.25 ** 
IL-10 OOR 1.19±1.69 
IL-12 23.97 ± 3.11 66.72 ± 11 * 
IL-13 OOR 19.24±2.46 
IL-15 OOR OOR 
IL-17 OOR OOR 
Eotaxin 0.09 ± 0.01 88 ± 24.45 ** 
FGF basic 11.30±10.71 OOR 
G-CSF 2.11±166 18.66±16.03 
GM-CSF 10.22±9.28 39.93±24.54 
IFN-g 47.26±31.76 382.04±237.34 
IP-10 OOR 2.48±1.51 
MCP-1 OOR 8.56±7.10 
MIP-1° 4.11±3.12 1.75±2.47 
MIP-1b 0.33±0.28 OOR 
RANTES 15.24 ± 1.45 245.67 ± 24.25 ** 
TNF-a OOR 0.19± 0.27 
VEGF 117.29± 20.19 10134.32 ± 3785.37 ** 
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Table 3b. Twenty seven human cytokines and growth factors levels have been measured 
(data are reported as pg/ml). The most significantly modified are shown *= p<0.005 or 
**= p<0.001. ORR (Out Of Range) identifies analytes that are not detectable by the assay.  
(Lower or higher than the limit of detection). 
 
 
 
 
In the table 4 the results of different melanoma stem cell clones at three different 
differentiation stages are reported. Mel SC (melanoma stem cells), Mel PC(differentiating 
cells) and Mel PC
+
 (differentiated cells) show different cytokine levels related to the 
differentiation stage. Data indicate that PDGF-bb, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-15, Il-17, Eotaxin, FGF basic, GM-CSF, IFN-g, IP-10, MCP-1, TNF-α  were not 
modified in both cell extracts and conditioned media, in the three conditions. On the 
contrary, MIP-1 α, MIP-1 β, RANTES, VEGF, IL-7, IL-12, IL-13 are high in SC, rise in 
PC and decrease in PC
+
. IL-9 and IL-1 β levels are increase in PC and in PC+ compared 
to SC cells and therefore, these levels are increased in PC
+
 compared to PC cells.  
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Figure 12.  SC and PC human melanoma stem cells (kindly purchased from Dr. Adriana 
Eramo, ISS). (Sette et al., 2013) 
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CYTOKINES LEVELS IN CELL EXTRACTS 
 Mel 1 SC Mel 1 PC Mel 1 PC
+
 
PDGF-bb  12.45±1.25 7.55±0.76 9.32±0.93 
 IL-1b 8.20±0.82 432.74±287.07 453.78±326.59 
 IL-1ra  3.22±0.32 5.52±4.04 7.06±0.71 
 IL-2  14.22±20.08 40.48±44.55 40.58±48.10 
 IL-4  2.70±0.27 0.80±0.08 1.35±0.92 
 IL-5  1.63±0.16 1.69±1.23 1.70±2.09 
 IL-6  OOR OOR OOR 
 IL-7  2.17±0.22 453.55±599.67 44.00±21.41 
 IL-8  OOR OOR OOR 
 IL-9  256.86±286.86 20933.61±15561.24 4807.36±3176.37 
 IL-10  14.56±1.46 7.92±7.12 16.40±1.64 
 IL-12  0.88±0.09 5.76±6.51 5.74±0.57 
 IL-13  3.66±0.37 14.03±14.07 10.60±12.61 
 IL-15  1.33±0.13 1.69±0.17 3.83±0.38 
 IL-17  1.56±0.16 OOR OOR 
 Eotaxin  OOR OOR OOR 
FGF basic  OOR OOR OOR 
 G-CSF  67.31±34.64 98.41±106.64 115.10±29.20 
GM-CSF  17.98±1.80 42.63±33.82 28.30±34.38 
 IFN-g  79.47±7.95 22.66±14.30 41.20±50.18 
 IP-10  27.98±2.80 37.13±26.52 67.74±6.77 
 MCP-1  OOR 72.85±11.78 39.22±32.70 
 MIP-1a  151.36±177.48 678.92±931.06 334.83±184.25 
 MIP-1b  44.91±12.43 402.13±352.84 136.51±24.67 
RANTES  41.44±4.14 462.27±448.56 227.98±245.61 
 TNF-a  3.77±0.38 14.55±1.46 13.15±1.31 
 VEGF  147.45±14.75 1856.48±1676.98 759.71±958.24 
 
Table 4a. Twenty seven human cytokines and growth factors levels have been measured 
(data are reported as pg/ml). 
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CYTOKINES LEVELS IN CONDITIONED MEDIA 
   Mel 1 SC Mel 1 PC Mel 1 PC
+
 
 PDGF-bb  0.15±0.01 9.56±0.96 0.30±0.03 
 IL-1b  1.63±0.77 26.65±15.53 27.16±28.00 
 IL-1ra  250.19±215.60 48.15±17.55 158.19±218.43 
 IL-2  15.44±5.79 22.35±10.52 23.94±11.66 
 IL-4  0.90±0.14 2.03±0.49 2.22±0.22 
 IL-5  0.43±0.07 1.20±0.62 1.79±0.18 
 IL-6  ORR ORR ORR 
 IL-7  14.99±10.72 415.59±140.28 236.67±314.39 
 IL-8  ORR ORR 1.10±0.11 
 IL-9  4514.39±3236.60 ORR 8123.97±638.02 
 IL-10  6.75±1.87 12.46±7.76 11.82±6.82 
 IL-12  3.73±1.07 18.70±7.90 22.57±14.92 
 IL-13  27.82±14.38 46.07±11.86 43.46±15.83 
 IL-15  0.26±0.03 1.11±0.11 ORR 
 IL-17  1.92±1.89 3.27±2.84 1.44±0.14 
 Eotaxin  ORR ORR ORR 
 FGF basic  6.39±0.64 14.84±1.48 9.20±0.92 
 G-CSF  1909.68±728.94 68.16±48.62 1353.21±1355.41 
 GM-CSF  3.84±3.30 683.35±657.20 723.79±1014.64 
 IFN-g  8.98±1.92 24.10±10.65 17.11±14.47 
 IP-10  7.61±4.54 32.82±6.27 16.26±20.59 
 MCP-1  844.79±737.90 1258.29±520.14 981.96±56.81 
 MIP-1a  524.35±230.26 818.89±320.58 831.53±511.17 
 MIP-1b  604.11±370.62 539.63±163.21 1012.14±500.24 
 RANTES  410.88±91.97 1128.06±513.12 1750.77±279.28 
 TNF-a  1.97±0.20 8.27±2.06 7.51±2.08 
 VEGF  3384.90±947.46 11785.19±14787.10 6035.58±3102.81 
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Table 4b. Twenty seven human cytokines and growth factors levels have been measured 
(data are reported as pg/ml). 
 
V. Proteomic studies - Mass Spectrometry Analysis  
Cell extracts were treated and then separated as above reported. The protein bands were 
detected in the gels by silver staining procedure. Bands were cut and digested as reported. 
The cell proteome was analyzed and the total number of identified proteins was 
calculated. The UNIQUE proteins, i.e. those uniquely expressed in just one of the two cell 
lines, A375 or SK mel 28 melanoma cells, represent the most interesting candidates, 
directly or indirectly playing a role as molecules/pathways responsible for their different 
aggressiveness. 
We identified in A375 cells 326 unique proteins out of 836 total proteins and in SK mel 
28 186 unique proteins out of 696 total proteins. Therefore 510 common proteins were 
identified in both cell lines (Figure 11).  
 
 
 
Figure 13. Schematic representation of common and unique proteins in A375 and SK mel 
28 cell lines.   
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VI. Proteomic studies -  Data Analysis  
The obtained proteomic results indicated a large number of unique proteins that were 
analyzed by a Gene Ontology and clustering screening through DAVID software 6.7 
version (http://david.abcc.ncifcrf.gov/). In the table 4 the functional data of A375 cells 
obtained from GO analysis are reported, were proteins expressed only in SK mel 28 (less 
aggressive cells) were compared and classified by means of DAVID features to those 
expressed in A375 (more aggressive cells) only. Results were compared and functional 
pathways present in A375 but absent in SK mel 28 were identified. In particular, by the 
clustering analysis (Figure 14), the following pathways were recognized in SK mel 28 
cell line: aminoacyl-tRNA biosynthesis, citrate cycle (TCA cycle), pentose phosphate 
pathway, selenoamino acid metabolism, fructose and mannose metabolism pathways. 
These pathways were identified in A375:  butanoate metabolism, amino sugar and 
nucleotide sugar metabolism, endocytosis, spliceosome, insulin signaling pathway and 
others. Different common pathways were also identified like valine, leucine and 
isoleucine degradation, ribosome, proteasome, fatty acid metabolism, glycolysis / 
gluconeogenesis, pyruvate metabolism (Table 5). To make easier the interpretation of 
results, presently only pathways identified with more than 3% of the unique proteins have 
been reported, although a careful analysis of the whole body of results is ongoing by 
taking into account also categories/pathways represented by groups of protein 
corresponding to less than 3% of total. 
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Pathways  A375 SK mel 28 
% 
Value  
n° of  
proteins 
% 
Value  
n° of  
proteins 
Valine, leucine and isoleucine 
degradation 
7,69 10 8,22 6 
Ribosome 9,23 12 19,18 14 
Proteasome 6,93 9 9,59 7 
Fatty acid metabolism 6,16 8 5,48 7 
Glycolysis / Gluconeogenesis 4,62 6 9,59 4 
Pyruvate metabolism 3,85 5 10,96 8 
Butanoate metabolism 4,62 6 < 3
 
or 
absent 
< 3
 
or 
absent 
Amino sugar and nucleotide sugar 
metabolism 
4,62 6 < 3
 
or 
absent 
< 3
 
or 
absent 
Endocytosis 10,00 13 < 3
 
or 
absent 
< 3
 
or 
absent 
Spliceosome 6,93 9 < 3
 
or 
absent 
< 3
 
or 
absent 
Insulin signaling pathway 6,93 9 < 3
 
or 
absent 
< 3
 
or 
absent 
Aminoacyl-tRNA biosynthesis < 3
 
or 
absent 
< 3
 
or 
absent 
13,70 10 
Citrate cycle (TCA cycle) < 3
 
or 
absent 
< 3
 
or 
absent 
6,85 5 
Pentose phosphate pathway < 3
 
or 
absent 
< 3
 
or 
absent 
5,48 4 
Selenoamino acid metabolism < 3
 
or 
absent 
< 3
 
or 
absent 
5,48 4 
Fructose and mannose metabolism < 3
 
or 
absent 
< 3
 
or 
absent 
5,48 4 
Others…  32,29 26 < 3
 
or 
absent 
< 3
 
or 
absent 
 
 
Table 4. Schematic report of the David classification analysis. To make easer data 
evaluation only pathways identified with more than 3% of the unique proteins have been 
reported. 
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Figure 14a. Schematic representation of the David classification analysis. Unique 
proteins, i.e. expressed in SK mel 28 only and absent in A375 cell line, were considered.  
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Figure 14b. Schematic representation of the David classification analysis. Unique 
proteins, i.e. expressed in A375 only and absent in SK mel 28 cell line, were considered.  
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Table 5. Schematic report of the David Gene Ontology analysis.  
 
 
A further Gene Ontology analysis using DAVID software 6.7 version 
(http://david.abcc.ncifcrf.gov/) (Figure 15) was performed also on the proteins obtained 
from the MS analysis and results are reported in the table 5. A375 proteins were pooled in 
Functional 
Classification 
A375 SK mel 28 
% Value n° of proteins % Value n° of proteins  
acetylation 19.34 182 18.36 108 
cytoplasm 13.50 127 10.2 60 
mitochondrion 5.42 51 < 3
 
or absent < 3
 
or absent 
transit peptide 3.83 36 < 3
 
or absent < 3
 
or absent 
phosphoprotein 19.77 186 20.92 123 
protein transport 3.40 32  < 3
 
or absent 13 
oxidoreductase 3.40 32  < 3
 
or absent  10 
disease mutation 6.16 58  < 3 or absent  26 
nucleotide-
binding 
6.06 57 7.48 44 
endoplasmic 
reticulum 
2.98 28   < 3 or absent  16 
transport 5.10 48 < 3
 
or absent < 3
 
or absent 
RNA-binding  <3
 
or absent 16 4.25 25 
ribonucleoprotein 1,59 15 3.06 18 
ATP-binding < 3
 
or absent 38 4.76 28 
nucleus < 3
 
or absent < 3
 
or absent 10.71 63 
Others 11.06 104 20.24 119 
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different functional categories as mitochondrion, transit peptide, protein transport, 
oxidoreductase, disease mutation, endoplasmic reticulum, transport. SK mel 28 proteins 
were pooled in RNA-binding, ribonucleoprotein, ATP-binding, nucleuos functional 
categories. Both A375 and SK mel 28 unique proteins were clustered in cytoplasm, 
phosphoprotein, nucleotide-binding and acetylation cathegories.  
 
 
 
 
Figure 15a. Schematic representation of David analysis for functional classification. 
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Figure 15b. Schematic representation of David analysis for functional classification. 
 
VII. Validation of proteomic data by correlation to GEO dataset  
To confirm this preliminary analysis, we compared our results obtained through 
proteomic and Bio-Plex analyses to a gene expression dataset concerning human 
metastatic melanoma, at the NCBI's Gene Expression Omnibus (GEO) database (Neveol 
et al., 2012).  In particular the dataset GDS1314, 
(http://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS1314 ) was examinated. This 
dataset analyzed contains expression profiling of Mel JUSO, A375, 607B, 518A2, and SK 
mel 28 malignant melanoma cell lines. Results correlated with regions of chromosomal 
breakpoints, and indicate an association between chromosomal breakpoints and altered 
gene expression. By the dataset analysis, we obtained gene expression of IL-1ra, IL-6, IL-
7 and Rantes. We compared the GEO results to the proteomic analysis (Bio-Plex assays 
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above reported) and data showed that, choosing SK mel 28 as control (100%), Rantes, IL-
6 and IL-7 are increased in A375 in both transcriptomic and proteomic analysis, while IL-
1ra decreased in A375 in the same analysis (Figure 16).   
 
 
Figura 16. Bio-Plex and GEO analysis comparison. A375 cytokines increase by 
trascriptomic and proteomic analysis compared to SK mel 28 as control.    
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Another study available through GEO Series accession number GDS1375 from a 
cutaneous malignant melanoma study 
(http://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS1375 ) was analyzed. This 
dataset contains expression profiling of primary malignant melanoma (n= 45), benign 
skin nevi (n=18), and normal skin samples (n=7) (Talantov et al., 2005). 
Results identify potential molecular markers for lymph node staging assays, and provide 
insight into melanoma tumorigenesis. Searching for cytokines expression into the study 
dataset, we found several findings confirming the data obtained in cell lines and cancer 
stem cell clones. In particular, we found that 3 out of 5 present in the dataset, namely IL-
1ra, IL-7 and VEGF were significantly modified and in the same way modulated (Figure 
17).  
 
Figura 17.  GDS1314 GEO analysis. Cytokines significantly modified in human 
metastatic melanoma patients compared to healthy individuals. 
In Figure 18 a schematic representation of cytokines level expressed in three different 
models is reported. 
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Figure 18. Schematic representation of cytokines level expressed in three different 
models such as the most aggressive (A375) versus the less aggressive (SK mel 28) 
melanoma cell lines; the most aggressive (SC) versus the less differentiated (PC)and  the 
most aggressive (SC) versus the most differentiated (PC
+
) melanoma stem cells the most 
aggressive (A375) versus the less aggressive (SK mel 28)according to the GEO analysis. 
Green box means downregulation; red box means upregulation; grey box means not 
modified expression; empty box indicates un-matched condition.  1 box means 1-3 fold 
modulation; 2 boxes means 3-8 fold modulation; 3boxes means 8 to higher fold 
modulation. Statistical significance was always very high (p<0.001).
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5. DISCUSSION & CONCLUSION 
      
 
Concept Flow 
 
 
 
 
Human metastatic melanoma is a devastating skin cancer characterized by a poor 
prognosis (Mathieu et al., 2012). Due to the lack of therapeutic strategies against 
advanced stages, there is an urgent need of novel therapeutic approaches to contrast the 
molecular mechanism underlying the fast progression and metastatic process. In the 
mechanisms related to melanoma aggressiveness to find novel melanoma modulators was 
analyzed. At first we selected as model of study several melanoma cell lines and we 
performed a growth assay at three different densities of seeding and in serum deprivation 
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conditions. This analysis led to identify cells that, under extreme stimuli conditions, show 
adaptive and reactive traits.  As above reported we identified two groups of cell lines 
highly different for proliferation rate, confirmed by in vitro invasion assays, and we 
selected as model the less (SK mel 28) and the most (A375) aggressive cell lines. In fact 
the proliferation assay showed that A375 cells behave very high growth rate compared to 
SK mel 28 cells at three different cell density. Moreover, results suggested a key role 
played by cell signaling mechanisms like secretory stimuli and/or cell-cell interaction. As 
shown in figure 8, a high proliferation rate was revealed in A375 cells after 24 and 48 
hours compared to SK mel 28, that presented a low proliferation at the same time. A375 
cells in the time between 24 and 48 hours of growth showed the same trend that may be 
explained by a high expression of adhesion and secretory molecules that stimulate the 
surrounding cells to proliferate.  
These observations were confirmed carrying out an invasion assay demonstrating that 
A375 are more invasive and therefore, more aggressive than SK mel 28. Therefore the 
reason of this higher aggressiveness was investigated. It is known that differentiation is 
closely related to aggressiveness (Mohlin et al., 2011 ), many literature data, in fact, 
reported important anticancer effects of phytochemicals linked to the induction of tumor 
cell differentiation, through the activation of intracellular transglutaminase (TGase; EC 
2.3.2.13) (Facchiano et al. 2006; Lentini et al. 2010; Lentini et al., 2000), an enzyme 
involved in melanoma progression. Previously reported, using proteomic approaches we 
identified a number of possible players in melanoma aggressiveness, to be further 
investigated. In fact, by a comparative analysis between several melanoma models with 
different aggressivity, IL-6, IL-12, VEGF, IL-7, IL-9, Eotaxin, RANTES, PDGF-bb, IL-
17, INF-γ and G-CSF were identified as positive modulators of aggressiveness. 
To verify these data, a biochemical validation using GEO dataset was performed and IL-
6, IL-7 and RANTES were confirmed to be related to a high aggressiveness.  
In previous studies an increasing level of RANTES was related to metastatic 
dissemination (Mrowietz et al., 1999) and promotes the IL-1b expression which in turn, in 
other studies, was demonstrated to stimulate the IL-6 increase (Li et al., 2009). To further 
investigate these preliminary results, the differential protein expression was studied and it 
is noteworthy that one of identified interesting pathways was the selenoamino acid 
metabolism. Selenocystine (SeC), a naturally occurring selenoamino acid, has an 
anticancer activity triggering the apoptosis process in human metastatic melanoma cell 
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lines through the activation of the mitochondria-mediated and death receptor-mediated 
apoptosis pathways (Chen and Wong, 2008). The matching of literature reports with our 
proteomic results confirms that our approach is useful and reliable and allows to 
hypothesize that this pathways play a key role in melanoma aggressiveness. To identify 
additional putative players responsible of the aggressiveness, through a DAVID analysis 
the functional classifications was studied and the attention was focused on proteins 
transport and proteins related to proteasome which we found more expressed in A375 
than in SK mel 28 cells. E3 ubiquitine-protein ligase NEDD4 (E3 Ub ligase NEDD4, also 
known as cell proliferation-inducing gene 53) is an ubiquitylation mediator. Melan-
A/MART-1 (also called Melan-A) is a protein expressed by melanocytic cells (Romero et 
al., 2002). Melan-A interacts with E3 Ub and so it can be degraded in the lysosomes; the 
resulted peptides are exposed on the surface of the melanoma cells. So ubiquitylation of a 
melanosomal protein concerns its sorting and degradation and could therefore impact on 
pigmented cells (Levy et al., 2005). 
Aberrant cellular proliferation and damaged apoptotic pathways are traits of cancer 
aggressiveness; proteasome is involved in both processes. A high proteasome activity is 
related to an absent apoptosis activity as seen in cancer progression and  some inhibitories 
were used to block the proteasome activity and therefore, to induce apoptotic process 
(Cecarini et al., 2011). So, the inhibition of proteasome is a strategy to contrast cancer 
progression. On the basis of these observations,  and above all based on our reported 
proteomic results we can hypothesize that in our aggressive cells, proteasome activity can 
be related to the high malignancy. 
In conclusion we identified cell lines that differ for malignancy, in particular A375 are 
more aggressive than SK mel 28. Using an immunometric analysis we identified several 
cytokines probably involved in cutaneous melanoma aggressiveness such as IL-6, IL-7, 
RANTES and VEGF and others (SEE Table 6). In vivo these molecules are involved in 
inflammation, immune response, apoptosis and angiogenesis processes, so it can be 
possible that modulating their expression could act on the melanoma metastatic 
dissemination process. The following molecular pathways likely very important to 
explain the higher cell aggressiveness were identified:  selenoamino acid metabolism 
involved in apoptosis process and proteasome activity. In vitro and in vivo validation 
studies are presently ongoing to demonstrate these interesting findings, with the aim to 
develop novel strategies against cutaneous melanoma.  
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Table 6. Cytokines involved as positive (green arrows) or negative (red arrows) 
modulators of human melanoma cell aggressiveness. 
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